AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 3 - (NewsRx.com & NewsRx.net) -- Although Phase II results are promising, more research is needed to evaluate the safety and efficacy of intensity-modulated radiotherapy (IMRT), researchers say.
"Intensity-modulated radiotherapy is a novel conformal radiotherapy technique which is gaining increasingly widespread use," researchers in England report.
"This second clinical article aims to summarize the published data pertaining to prostate cancer, pelvic irradiation, gynecological, and breast cancer. Prostate cancer patients represent the largest group treated to date," wrote M.T.G. Urbano and colleagues, Royal Marsden NHS Trust, Head & Neck Unit.
"The main indication has been radiation dose escalation within acceptable normal tissue late toxicity. Phase II data are promising, but no randomized clinical trial data are available to support its use. Pelvic IMRT aims to deliver radical radiation doses to pelvic lymph nodes while sparing the bowel and ...
Source: HighBeam Research, Intensity-modulated radiotherapy appears promising for pelvic cancers.